Seoul Bio C&V (CEO Lee Seong-kwon), a non-clinical trial contract research organization (CRO), announced on the 24th that it signed a business agreement (MOU) to strengthen strategic research cooperation with Inje University Busan Baek Hospital (Director Yang Jae-wook) and the Ministry of Health and Welfare-designated Ophthalmology Disease Effectiveness Evaluation Center (Director Yang Jae-wook).
This agreement mainly includes comprehensive cooperation in research planning centered on ophthalmic diseases, commissioned research, efficacy evaluation at the new drug development stage, and clinical linkage services. Through mutual cooperation, the three organizations plan to enhance R&D competitiveness in the field of ophthalmic diseases and contribute to research efficiency and dissemination of results.
Inje University Busan Paik Hospital Ophthalmology Disease Effectiveness Evaluation Center is an independent center established through the Ministry of Health and Welfare's 'Disease Effectiveness Evaluation Center' project, and is playing a leading role in the domestic ophthalmology disease effectiveness evaluation field based on a global-level evaluation infrastructure and a medical institution-linked advisory system.
Through this agreement, Seoul Bio C&V plans to expand its cooperation network with major domestic medical institutions in various disease areas including ophthalmic diseases and further strengthen its non-clinical trial quality management capabilities based on GLP (Good Laboratory Practices). Through this, it expects to improve data reliability in the non-clinical stage and efficiency in the early stages of new drug development.
Yang Jae-wook, the president of Busan Baek Hospital, said, “I hope this agreement will become an exemplary case of an integrated service model that connects clinical and non-clinical care.”
Lee Seong-kwon, CEO of Seoul Bio C&V, said, “We expect to maximize the synergy between non-clinical and clinical research through collaboration with university hospitals,” and “In particular, opportunities for rodent model-based convergence research in the field of ophthalmic diseases will expand.”
- See more related articles
You must be logged in to post a comment.